 Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 6 | 7 | | 1996 | 1 | 2 | 3 | | 1997 | 1 | 5 | 6 | | 1998 | 0 | 4 | 4 | | 1999 | 4 | 4 | 8 | | 2000 | 3 | 6 | 9 | | 2001 | 2 | 3 | 5 | | 2002 | 3 | 3 | 6 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 4 | 6 | | 2005 | 6 | 8 | 14 | | 2006 | 3 | 12 | 15 | | 2007 | 5 | 4 | 9 | | 2008 | 8 | 5 | 13 | | 2009 | 12 | 14 | 26 | | 2010 | 13 | 14 | 27 | | 2011 | 12 | 11 | 23 | | 2012 | 13 | 3 | 16 | | 2013 | 11 | 16 | 27 | | 2014 | 29 | 4 | 33 | | 2015 | 11 | 8 | 19 | | 2016 | 12 | 9 | 21 | | 2017 | 23 | 10 | 33 | | 2018 | 21 | 7 | 28 | | 2019 | 23 | 11 | 34 | | 2020 | 20 | 26 | 46 | | 2021 | 14 | 27 | 41 | | 2022 | 5 | 31 | 36 | | 2023 | 0 | 42 | 42 | | 2024 | 1 | 6 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv. 2024 07 09; 8(13):3507-3518.
-
Schulick AC, Moore HB, Franco SR, Jiang JG, Edil BH, Schulick RD, Nydam TL, McCarter MD, Del Chiaro M, Gleisner A. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampullary and pancreatic adenocarcinoma. Am J Surg. 2024 Dec; 238:115820.
-
Keller AL, Reiman LT, Perez de Acha O, Parzych SE, Forsberg PA, Kim PS, Bisht K, Wang H, van de Velde H, Sherbenou DW. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies. Cancer Res Commun. 2024 03 12; 4(3):757-764.
-
Cucinella G, Schivardi G, Zhou XC, AlHilli M, Wallace S, Wohlmuth C, Baiocchi G, Tokgozoglu N, Raspagliesi F, Buda A, Zanagnolo V, Zapardiel I, Jagasia N, Giuntoli R, Glickman A, Peiretti M, Lanner M, Chacon E, Di Guilmi J, Pereira A, Laas-Faron E, Fishman A, Nitschmann CC, Kurnit K, Moriarty K, Joehlin-Price A, Lees B, Covens A, De Brot L, Taskiran C, Bogani G, Landoni F, Grassi T, Paniga C, Multinu F, De Vitis LA, Hern?ndez A, Mastroyannis S, Ghoniem K, Chiantera V, Shahi M, Fought AJ, McGree M, Mariani A, Glaser G. Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study. Int J Gynecol Cancer. 2024 Feb 05; 34(2):179-187.
-
Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, Crooks K, Gignoux C, Cohen T. Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules as Benign or Malignant. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):402-412.
-
Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, O'Reilly EM. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb; 30(2):531-542.
-
Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica. 2024 01 01; 109(1):209-219.
-
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2024 Apr 01; 42(10):1146-1157.
-
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 12; 21(12):1281-1301.
-
Han S, Turkeltaub JA, Jonas D, Attwell AR, Duloy AM, Edmundowicz SA, Hammad HT, Wagh MS, Wani S, Shah RJ. The timing of recurrence after endoscopic papillectomy. Surg Endosc. 2024 Feb; 38(2):688-696.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|